Cell Signaling Technology Logo
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ZBTB46 (F6Z3F) Rabbit mAb #72742

Filter:
  • WB
  • IP
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 80-100
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Flow Cytometry (Fixed/Permeabilized) 1:500 - 1:1500

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    ZBTB46 (F6Z3F) Rabbit mAb recognizes endogenous levels of total ZBTB46 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ZBTB46 protein.

    Background

    Zinc finger and BTB domain-containing protein 46 (ZBTB46) is a member of the broad complex zinc finger protein family, which plays a critical role in transcriptional regulation of immune response, tumor microenvironment, and hematopoietic differentiation (1-3). ZBTB46 is often expressed in dendritic cells (DCs) and their committed progenitors, and is used as a marker to distinguish them from other immune cell types (3,4). ZBTB46 has been shown to act as a transcriptional repressor in these cell types, maintaining a homeostatic steady state; however, it was shown to be non-essential for DC development (3,8). ZBTB46 is also expressed in quiescent endothelial cells and was shown to inhibit cell proliferation (3,4). Recent work has focused on the role of ZBTB46 in tumors. In breast cancer, ZBTB46 was shown to upregulate a long non-coding RNA (lncRNA) that can control breast cancer progression by manipulating tumor immune response (5). A fusion gene consisting of ZBTB46 and WFDC13 is a novel therapeutic target candidate in high-grade serous ovarian carcinoma (6). ZBTB46 is highly expressed and promotes upregulation of inflammation response and neuroendocrine differentiation genes in prostate cancer (7).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.